Overexpression of serotonin receptor and transporter mRNA in blood leukocytes of antipsychotic-free and antipsychotic-naïve schizophrenic patients: Gender differences

Schizophrenia Research

Volumn 121, Issue 1-3, 2010, Pages 160-171

  Wang, Gang ^a   Hu, Changqing ^a   Jiang, Tao ^a   Luo, Jiong ^a   Hu, Jian ^b   Ling, Sihai ^a   Liu, Min ^a   Xing, Guoqiang ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Drug free schizophrenia; Leukocytes; MRNA; Serotonin receptor and transporter

Indexed keywords

MESSENGER RNA; NEUROLEPTIC AGENT; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 7 RECEPTOR; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; DRUG EXPOSURE; FEMALE; GENE OVEREXPRESSION; GENETIC MARKER; HUMAN; HUMAN CELL; LEUKOCYTE; MALE; NUCLEOTIDE SEQUENCE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHIZOPHRENIA; SEX DIFFERENCE; ANALYSIS OF VARIANCE; BLOOD; CASE CONTROL STUDY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHYSIOLOGY; SEXUAL DEVELOPMENT;

ADULT; ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LEUKOCYTES; MALE; RECEPTORS, SEROTONIN; RNA, MESSENGER; SCHIZOPHRENIA; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEX CHARACTERISTICS;

EID: 77955054539     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2010.03.030     Document Type: Article

References (41)

1. Abi-Saab W., Seibyl J.P., D'Souza D.C., Karper L.P., Gueorgueva R., Abi-Dargham A., et al. Ritanserin antagonism of m-chlorophenylpiperazine effects in neuroleptic-free schizophrenics patients: support for serotonin-2 receptor modulation of schizophrenia symptoms. Psychopharmacology (Berl) 2002, 162:55-62.
2. Anderson D.J., Puttfarcken P.S., Jacobs I., Faltynek C. Assessment of nicotinic acetylcholine receptor-mediated release of [(3)H]-norepinephrine from rat brain slices using a new 96-well format assay. Neuropharmacology 2000, 39:2663-2672.
3. Arranz B., Rosel P., Sarro S., Ramirez N., Duenas R., Cano R., et al. Altered platelet serotonin 5-HT2A receptor density but not second messenger inositol trisphosphate levels in drug-free schizophrenic patients. Psychiatry Res. 2003, 118:165-174.
4. Arranz B., Rosel P., San L., Ramirez N., Duenas R.M., Salavert J., et al. Low baseline serotonin-2A receptors predict clinical response to olanzapine in first-episode schizophrenia patients. Psychiatry Res. 2007, 153:103-109.
5. Barkan T., Peled A., Modai I., Barak P., Weizman A., Rehavi M. Serotonin transporter characteristics in lymphocytes and platelets of male aggressive schizophrenia patients compared to non-aggressive schizophrenia patients. Eur. Neuropsychopharmacol. 2006, 16:572-579.
6. Barkan T., Peled A., Modai I., Weizman A., Rehavi M. Characterization of the serotonin transporter in lymphocytes and platelets of schizophrenia patients treated with atypical or typical antipsychotics compared to healthy individuals. Eur. Neuropsychopharmacol. 2006, 16:429-436.
7. Bleuler M. Thoughts on the present theory of schizophrenia, with reference to concepts of constitutional pathology. Wien. Z. Nervenheilkd. Grenzgeb 1953, 7:255-270.
8. Brusov O.S., Faktor M.I., Zlobina G.P., Dupin A.M., Katasonov A.B., Dmitriev A.D., et al. Platelet serotonergic parameters and clinical symptoms of psychosis in patients with episodic progressive schizophrenia. Zh Nevrol. Psikhiatr. Im SS Korsakova 2007, 107:17-24.
9. Caspi N., Modai I., Barak P., Waisbourd A., Zbarsky H., Hirschmann S., et al. Pindolol augmentation in aggressive schizophrenic patients: a double-blind crossover randomized study. Int. Clin. Psychopharmacol. 2001, 16:111-115.
10. Compton J., Travis M.J., Norbury R., Erlandsson K., van Amelsvoort T., Daly E., et al. Long-term estrogen therapy and 5-HT2A receptor binding in postmenopausal women: a single photon emission tomography (SPET) study. Horm. Behav. 2008, 53:61-68.
11. Dean B., Hayes W. Decreased frontal cortical serotonin2A receptors in schizophrenia. Schizophr. Res. 1996, 21:133-139.
12. DeLisi L.E., Neckers L.M., Weinberger D.R., Wyatt R.J. Increased whole blood serotonin concentrations in chronic schizophrenic patients. Arch. Gen. Psychiatry 1981, 38:647-650.
13. Ertugrul A., Ucar G., Basar K., Demir B., Yabanoglu S., Ulug B. Influence of clozapine on platelet serotonin, monoamine oxidase and plasma serotonin levels. Psychiatry Res. 2007, 149:49-57.
14. Faraone S.V., Chen W.J., Goldstein J.M., Tsuang M.T. Gender differences in age at onset of schizophrenia. Br. J. Psychiatry 1994, 164:625-629.
15. Garelis E., Gillin J.C., Wyatt R.J., Neff N. Elevated blood serotonin concentrations in unmediated chronic schizophrenic patients: a preliminary study. Am. J. Psychiatry 1975, 132:184-186.
16. Govitrapong P., Chagkutip J., Turakitwanakan W., Srikiatkhachorn A. Platelet 5-HT(2A) receptors in schizophrenic patients with and without neuroleptic treatment. Psychiatry Res. 2000, 96:41-50.
17. Govitrapong P., Mukda S., Turakitwanakan W., Dumrongphol H., Chindaduangratn C., Sanvarinda Y. Platelet serotonin transporter in schizophrenic patients with and without neuroleptic treatment. Neurochem. Int. 2002, 41:209-216.
18. Gurevich E.V., Joyce J.N. Alterations in the cortical serotonergic system in schizophrenia: a postmortem study. Biol. Psychiatry 1997, 42:529-545.
19. Hernandez I., Sokolov B.P. Abnormal expression of serotonin transporter mRNA in the frontal and temporal cortex of schizophrenics. Mol. Psychiatry 1997, 2:57-64.
20. Holmes A., Yang R.J., Lesch K.P., Crawley J.N., Murphy D.L. Mice lacking the serotonin transporter exhibit 5-HT(1A) receptor-mediated abnormalities in tests for anxiety-like behavior. Neuropsychopharmacology 2003, 28:2077-2088.
21. Ikeda M., Iwata N., Kitajima T., Suzuki T., Yamanouchi Y., Kinoshita Y., et al. Positive association of the serotonin 5-HT7 receptor gene with schizophrenia in a Japanese population. Neuropsychopharmacology 2006, 31:866-871.
22. Joyce J.N., Shane A., Lexow N., Winokur A., Casanova M.F., Kleinman J.E. Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology 1993, 8:315-336.
23. Kane J.M., Leucht S., Carpenter D., Docherty J.P. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J. Clin. Psychiatry 2003, 64(Suppl 12):5-19.
24. Laruelle M., Abi-Dargham A., Casanova M.F., Toti R., Weinberger D.R., Kleinman J.E. Selective abnormalities of prefrontal serotonergic receptors in schizophrenia. A postmortem study. Arch. Gen. Psychiatry 1993, 50:810-818.
25. Lewis R., Kapur S., Jones C., DaSilva J., Brown G.M., Wilson A.A., et al. Serotonin 5-HT2 receptors in schizophrenia: a PET study using [18F]setoperone in neuroleptic-naive patients and normal subjects. Am. J. Psychiatry 1999, 156:72-78.
26. Modai I., Gibel A., Rauchverger B., Ritsner M., Klein E., Ben-Shachar D. Paroxetine binding in aggressive schizophrenic patients. Psychiatry Res. 2000, 94:77-81.
27. Naylor L., Dean B., Opeskin K., Pavey G., Hill C., Keks N., et al. Changes in the serotonin transporter in the hippocampus of subjects with schizophrenia identified using [3H]paroxetine. J. Neural Transm. 1996, 103:749-757.
28. Newman-Tancredi A., Assie M.B., Leduc N., Ormiere A.M., Danty N., Cosi C. Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia. Int. J. Neuropsychopharmacol. 2005, 8:341-356.
29. Okubo Y., Suhara T., Suzuki K., Kobayashi K., Inoue O., Terasaki O., et al. Serotonin 5-HT2 receptors in schizophrenic patients studied by positron emission tomography. Life Sci. 2000, 66:2455-2464.
30. Pandey G.N., Pandey S.C., Dwivedi Y., Sharma R.P., Janicak P.G., Davis J.M. Platelet serotonin-2A receptors: a potential biological marker for suicidal behavior. Am. J. Psychiatry 1995, 152:850-855.
31. Riecher-Rossler A., Hafner H. Gender aspects in schizophrenia: bridging the border between social and biological psychiatry. Acta Psychiatr. Scand. Suppl. 2000, 58-62.
32. Roth B.L., Craigo S.C., Choudhary M.S., Uluer A., Monsma F.J., Shen Y., et al. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J. Pharmacol. Exp. Ther. 1994, 268:1403-1410.
33. Semenova S., Geyer M.A., Sutcliffe J.G., Markou A., Hedlund P.B. Inactivation of the 5-HT(7) receptor partially blocks phencyclidine-induced disruption of prepulse inhibition. Biol. Psychiatry 2008, 63:98-105.
34. Shen Y., Monsma F.J., Metcalf M.A., Jose P.A., Hamblin M.W., Sibley D.R. Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype. J. Biol. Chem. 1993, 268:18200-18204.
35. Stahl S.M. Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. J. Affect. Disord. 1998, 51:215-235.
36. Sumiyoshi T., Stockmeier C.A., Overholser J.C., Dilley G.E., Meltzer H.Y. Serotonin1A receptors are increased in postmortem prefrontal cortex in schizophrenia. Brain Res. 1996, 708:209-214.
37. Takahashi S., Matsuura M., Tanabe E., Yara K., Nonaka K., Fukura Y., et al. Age at onset of schizophrenia: gender differences and influence of temporal socioeconomic change. Psychiatry Clin. Neurosci. 2000, 54:153-156.
38. Vollenweider F.X., Vollenweider-Scherpenhuyzen M.F., Babler A., Vogel H., Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport 1998, 9:3897-3902.
39. Xing G., Qualls C., Huicho L., Rivera-Ch M., Stobdan T., Slessarev M., et al. Adaptation and mal-adaptation to ambient hypoxia; Andean. Ethiopian and Himalayan patterns. PLoS ONE 2008, 3:e2342.
40. Yasuno F., Suhara T., Ichimiya T., Takano A., Ando T., Okubo Y. Decreased 5-HT1A receptor binding in amygdala of schizophrenia. Biol. Psychiatry 2004, 55:439-444.
41. Zhukovskaya N.L., Neumaier J.F. Clozapine downregulates 5-hydroxytryptamine6 (5-HT6) and upregulates 5-HT7 receptors in HeLa cells. Neurosci. Lett. 2000, 288:236-240.